Researchers have developed a soft, conductive electronic polymer mesh that can be injected into the brain to monitor and stimulate it at the level of individual neurons. They have published preclinical data on the device in the latest issue of Nature Nanotechnology.
The ability to supercool drug-carrying vesicles inside the body and time the exact moment of crystallization could lead to a targeted approach to drug delivery, researchers at Tel Aviv University have found.
Researchers in the lab of MIT's Robert Langer have created a hydrogel that's designed to be much better than current technologies in getting drugs into patients and straight to where they are targeted.
Researchers at Oregon State University have adapted a known molecule so that it sticks to cancer cells, opening up a new approach to better identifying tumors for surgical removal while providing a follow-up attack on any remaining malignant cells, helping to prevent the cancer from making a comeback.
Because nanoparticles are so different in scale from other drugs on the market, drugmakers will need a way to make them in bulk and at a low cost, though still highly specific in form and function. To that end, researchers have developed a technique for making 3-D structures at the nanoscale, offering repeatable production that is also relatively inexpensive.
Physicians can add another tool to their arsenal that targets chronic back pain locally, without requiring surgery or an external device. The FDA has cleared Stimwave's Freedom Spinal Cord Stimulation System, which the company says is the smallest available neuromodulation device.
An investigative team at the University of Cincinnati which specializes in nanotechnology says they've tested a new approach to destroying cancer cells--injecting the specific target cells with iron oxide nanoparticles and then using light-induced heat to burn them up.
Bind Therapeutics believes its lead nanoparticle treatment can make a difference for a subgroup of lung cancer patients, pointing to some positive results from an otherwise mixed mid-stage trial as it prepares for further study.
Google has dedicated more than 100 employees from multiple disciplines to making its vision of nanotechnology-enabled detection of cancer and other diseases a reality. Any tangible product resulting from this ambitious effort is at least 5 to 7 years away.
Researchers at NC State University and the University of North Carolina have developed a DNA-based delivery vehicle capable of acting as a Trojan horse in cancer cells. Using DNA as a cage instead of synthetic materials makes the vehicle less toxic to healthy cells and allows for the attachment of precise targeting mechanisms.